Clinical Trial Search

Primary: Proportion of Confirmed Tumor Response (Complete Response [CR], Unconfirmed CR, and Partial Response) — 0.48 proportion of participants

Primary: Aberrant Behavior Checklist — 7.1; 15.6; 9.6; 7.6 units on a scale

Primary: Positive and Negative Symptom Scores at Baseline and at 2 Weeks, 4 Weeks, and 6 Weeks During Intervention 1 (Glycine or Placebo), Intervention 2 (Glycine or Placebo)…

Primary: Response Rate, Defined as the Number of Patients Achieving Complete Response (CR), Partial Response (PR), or Minor Response (MR) — 5; 2; 3; 1 Participants

Primary: Percent Change From Baseline in Femoral Neck Bone Mineral Density (BMD) at Month 24 — 1.73; -0.94 Percent Change — p=<0.001

Primary: Objective Response Rates (Partial and Complete Responses) — 0 participants

Primary: 6-month Progression-free Survival (PFS) Rate — 0.792 proportion of patients progression-free

Primary: Number of Participants With Symptomatic Intracerebral Hemorrhage Within 36 Hours of Treatment — 0 participants

Primary: Count of Participants Who Self-reported "Adequate Relief" — 12; 15 Participants — p=0.59

Primary: Response (Complete and Partial Response) in Patients With Myeloid Disorders — 0; 1; 2; 5 Participants

Primary: Response Rate for Amrubicin in Patients With Metastatic or Advanced Sarcoma as First Line Therapy. — 13 percentage of pt with a partial response

Primary: Change in Oxygen Delivery in Vulnerable Brain Regions — 3.7; 4.3 ml/100g/min — p=0.001

Primary: Increase in ENK (Expanded Natural Killer Cells) Cells 7 Days After Treatment — 0 Participants

Primary: Number of Seroprotected Subjects Against Polyribosyl-Ribitol-Phosphate (PRP) — 126; 123; 130 Participants

Primary: Number of Subjects With Mixed Chimerism — 3; 8; 4 participants